Vertex Pharmaceuticals (VRTX), originally recommended by Crista Huff of Cabot Undervalued Stocks Advisor in her Buy Low Opportunities Portfolio, continues to consolidate in the 155 area after hitting a new high on excellent clinical data three weeks ago. In her latest update, Crista wrote, "Vertex is an undervalued, aggressive growth biotech company that corners the market in treatments for cystic fibrosis (CF). Consensus earnings estimates change weekly on VRTX. There are 24 analysts covering the stock, which is a high number vs. most other stocks. The company took a net loss of ($1.11) per share in 2015, then booked a profit of $0.85 per share in 2016. Analysts now expect EPS to reach $1.59 and $3.10 per share in 2017 and 2018, reflecting growth rates of 87.1% and 95.0%. The corresponding P/Es are 97.7 and 50.1, making the stock fully valued in 2017, but quite undervalued based on 2018 numbers. VRTX has pulled back after a rapid run-up in July.